Glenmark nets approval for generic of Mylan’s Olux-E foam in USA

Glenmark Pharmaceuticals said Tuesday it has bagged the final USFDA’s approval for its generic version of Mylan’s Olux-E Foam, Clobetasol Propionate Foam.

Glenmark refered to IQVIA’s sales data for the 12 month period ending July 2019, saying the Olux-E Foam market chieved annual sales of approximately $11.1 million.

Glenmark’s current portfolio consists of 161 products authorized for distribution in the U.S. marketplace and 54 ANDA’s pending approval with the U.S. FDA, it said in the press release. In addition to these internal filings, Glenmark said it will continue to “identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio”.